John P. Hamill - 27 Feb 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SrVP/CFO/Prin Fin & Acct Ofcr
Signature
/s/ John P. Hamill
Issuer symbol
APRE
Transactions as of
27 Feb 2023
Net transactions value
+$5,250
Form type
4
Filing time
27 Feb 2023, 17:37:13 UTC
Previous filing
30 Jan 2023
Next filing
14 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $5,250 +1,000 +7.4% $5.25 14,493 27 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective February 13, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.